IMAB – I-Mab ADR
I-MABIMAB
$0.97Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $79,056,072.00
EPSttm : -2.42
I-MAB
$0.97
0.35%$0.0034Float Short %
1.02
Margin Of Safety %
Put/Call OI Ratio
0.1
EPS Next Q Diff
0.1
EPS Last/This Y
EPS This/Next Y
-0.53
Price
0.97
Target Price
5.67
Analyst Recom
1
Performance Q
-3.96
Relative Volume
0.56
Beta
1.14
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | IMAB | 1.07 | 0.22 | 0.00 | 732 |
| 2025-01-24 | IMAB | 1.09 | 0.22 | 0.00 | 733 |
| 2025-01-27 | IMAB | 1.09 | 0.22 | 0.00 | 734 |
| 2025-01-28 | IMAB | 1.06 | 0.22 | 0.00 | 734 |
| 2025-01-29 | IMAB | 1.05 | 0.23 | 0.00 | 715 |
| 2025-01-30 | IMAB | 1.08 | 0.23 | 0.00 | 715 |
| 2025-01-31 | IMAB | 1.02 | 0.23 | 0.00 | 716 |
| 2025-02-03 | IMAB | 0.9518 | 0.22 | 0.00 | 745 |
| 2025-02-04 | IMAB | 0.96 | 0.22 | 0.00 | 745 |
| 2025-02-05 | IMAB | 0.9649 | 0.16 | 999.99 | 940 |
| 2025-02-06 | IMAB | 0.9798 | 0.18 | 0.09 | 950 |
| 2025-02-07 | IMAB | 0.9802 | 0.16 | 0.00 | 1005 |
| 2025-02-10 | IMAB | 0.946 | 0.13 | 5.00 | 1217 |
| 2025-02-11 | IMAB | 0.9674 | 0.13 | 0.00 | 1233 |
| 2025-02-12 | IMAB | 0.9548 | 0.12 | 0.00 | 1309 |
| 2025-02-13 | IMAB | 0.9578 | 0.10 | 0.00 | 1463 |
| 2025-02-14 | IMAB | 0.9573 | 0.10 | 0.00 | 1508 |
| 2025-02-18 | IMAB | 0.98 | 0.10 | 999.99 | 1538 |
| 2025-02-19 | IMAB | 0.9898 | 0.10 | 999.99 | 1538 |
| 2025-02-20 | IMAB | 0.9698 | 0.10 | 0.00 | 1536 |
| 2025-02-21 | IMAB | 0.97 | 0.10 | 0.00 | 1536 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | IMAB | 1.06 | - | - | -0.13 |
| 2025-01-24 | IMAB | 1.08 | - | - | -0.13 |
| 2025-01-27 | IMAB | 1.09 | - | - | -0.13 |
| 2025-01-28 | IMAB | 1.03 | - | - | -0.13 |
| 2025-01-29 | IMAB | 1.05 | - | - | -0.13 |
| 2025-01-30 | IMAB | 1.06 | - | - | -0.13 |
| 2025-01-31 | IMAB | 1.02 | - | - | -0.13 |
| 2025-02-03 | IMAB | 0.95 | - | - | -0.13 |
| 2025-02-04 | IMAB | 0.96 | - | - | -0.13 |
| 2025-02-05 | IMAB | 0.96 | - | - | -0.13 |
| 2025-02-06 | IMAB | 0.97 | - | - | -0.13 |
| 2025-02-07 | IMAB | 0.98 | - | - | -0.13 |
| 2025-02-10 | IMAB | 0.93 | - | - | -0.13 |
| 2025-02-11 | IMAB | 0.98 | - | - | -0.13 |
| 2025-02-12 | IMAB | 0.95 | - | - | -0.13 |
| 2025-02-13 | IMAB | 0.95 | - | - | -0.13 |
| 2025-02-14 | IMAB | 0.96 | - | - | -0.13 |
| 2025-02-18 | IMAB | 0.98 | - | - | -0.13 |
| 2025-02-19 | IMAB | 0.97 | - | - | -0.13 |
| 2025-02-20 | IMAB | 0.96 | - | - | -0.13 |
| 2025-02-21 | IMAB | 0.97 | - | - | -0.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | IMAB | 0.00 | -10.76 | 1.18 |
| 2025-01-24 | IMAB | 0.00 | -10.76 | 1.18 |
| 2025-01-27 | IMAB | 0.00 | -5.17 | 1.18 |
| 2025-01-28 | IMAB | 0.00 | -5.17 | 1.24 |
| 2025-01-29 | IMAB | 0.00 | -5.17 | 1.24 |
| 2025-01-30 | IMAB | 0.00 | -5.17 | 1.24 |
| 2025-01-31 | IMAB | 0.00 | -5.17 | 1.24 |
| 2025-02-03 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-04 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-05 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-06 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-07 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-10 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-11 | IMAB | 0.00 | -5.15 | 1.24 |
| 2025-02-12 | IMAB | 0.00 | -5.15 | 1.02 |
| 2025-02-13 | IMAB | 0.00 | -5.15 | 1.02 |
| 2025-02-14 | IMAB | 0.00 | -5.15 | 1.02 |
| 2025-02-18 | IMAB | 0.00 | -5.20 | 1.02 |
| 2025-02-19 | IMAB | 0.00 | -5.20 | 1.02 |
| 2025-02-20 | IMAB | 0.00 | -5.20 | 1.02 |
| 2025-02-21 | IMAB | 0.00 | -5.20 | 1.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.25
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
Institutional Transactions
-5.2
Beta
1.14
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
22
Growth Score
26
Sentiment Score
47
Actual DrawDown %
98.9
Max Drawdown 5-Year %
-99
Target Price
5.67
P/E
Forward P/E
PEG
P/S
67.92
P/B
0.32
P/Free Cash Flow
EPS
-1.55
Average EPS Est. Cur. Y
-0.13
EPS Next Y. (Est.)
-0.66
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-10901.66
Relative Volume
0.56
Return on Equity vs Sector %
-56
Return on Equity vs Industry %
-40.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.13
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 220
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading